We send the latest information from SMC Laboratories.
Today, we share an update regarding new preclinical service. It is now possible to use a positive control (Rof…
We would like to introduce a study published by our client using our STAM™ mouse (Dow, et al. Proc Natl Acad S…
Today, from our lineup of pathological models, we would like to introduce the imiquimod (IMQ)-induced dermatit…
Today, we introduce the pre-clinical studies in MASH drug development targeting GLP-1. Speaking of GLP-…
In recent years, we have received many requests about our services, starting from the establishment of patholo…
We introduce the pre-clinical studies in MASH drug development using Adiponectin, adipoR1 , adipoR2, etc. as M…
Today, we are excited to invite you to join our webinar that will be taking place on June 20 from 9:30 AM (JST…
If the therapeutic drug you are developing targets a factor that is related to a multi-organ pathology, such a…
We are pleased to announce that the latest pathology and pathogenesis data in the field of immuno-oncology on …
We are pleased to announce that SMC Laboratories will be exhibiting at The 110th General Meeting of the Japane…